Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

Th.(.47 78, 1.0.4779,1 h.C.A /86.
Th.C.4/87,. 60.4 /88, T6.(.4828.
36.C.A8'45, 1.[.230,T6.D.240,3 1))371,
Th.D '142,-1-0.[.446, [h.D.466, Th.D.4865,
-T-.D.4866, 1 h.DA4879,Th.D.4904.
Th. D.4908, -I h..4909, Th.(D.4915,
Yh.D.4986,.[.5000, 36 (.5006,
3 h.D.50 I 1, T h.D 5032,1 h [3504 I,
T6h.D.5055, 16 [),5079,TIh.D.5204,
Tu.B. 114,lTu.8.228/, lull2293,lu.[1.2299,
Tu.B.4 12. 1u.(.20 I,Tu.C.2 4, (3(1.2 5,
11(1.24 2 1 (.2622, Tci.(12650.
Tu.(1.33 I, Iu.C.333,Tu.(1.454,Tui.D 246,
3u.D.2/3 3, Tu.D.7/6,lTu [.2/797,
Tu.D.2804, Tu.D.2812, Iu [).2819,
Tu.D.283 I, u.D.2843,Tu.L.)865,
Tu.D 2869, (3(.28/STuD 2882,
Tu.D.2886,Tiu D.2925,lIu.D.2938,
Tu.D.2942, We.A.5 10, We.A 512,
We.B. 114,Wc (1.201,We.(1.204,
We.(1.205, We.(.350 I, We (1.35 lb.
We.(1.3542, We (1.35 /8, VWe.(.580,
We.D.233, We.D.372/, Ne.D.3728,
WeD.3742, We.D 3743, We.D. 3747,
We.D.3752 We.D.3/53. We.D 3755.
We.D. 3/59, We.D.3 7/3, We.D.3 /75,
We.D.377, /. D3//8,We 1.3/83,
We.D 3792, We.D.3 /93, We.[).Y95,
We.D.3803, We.D.3804. We D.3808,
We.D.3809, We.D.38 I0, WeT3.3826,
We.[).385 I, We.D.3864, We.L3.3889,
We.D 3898, VWe.D.590, We.D.6 1 2,
We.D.6 13
prevention, evaluation
Mu.1584. Mo.C. I1605. Mo.C. I1606,
M1cC. i 61 9, Mo.[-. I626, Mo.(.440,
Mo.(1.444, Mo..I 34. Mc.D I 752,
Ma.D.175 3, Mo.1. 1 759, Mo.D.17/0,
MoD. I17/2, Mo.3. 1773, MoD[. 1/79,
MoD.1782, MoD. 1/96, MoD. I1797,
MoD. 1/98, MoD. I80 I, [loll..I81I8.
MoD. 1819, MoD. 1820, Mo..1824,
Mo. I829, MoD. I1832, MoD,.I1842.
MoD.1923, MoD. I1936, Mo.D.580,
Mo.D.582, Pub (.1 167, Pub.C. 1 169,
Pub.C.1.I90, Pub.D. 1309. Publ). 1122,
Pub..114. PuIG..I450. Th.(1.2 14,
Th.C.4376, 1.(.4379.Th.(1.439 I,
T.C.4405. 16(1.4447,3 6 (14580,
Th.(1.4626, [6(1.4719. 16 (.4740.
Th.(.4750, 36.(.48 I1,.Th (.4812,
Th.(1.48 17,- cC.4826,16hC.4833,
T6.D. 136,1 h.D.36 I, [6.D. 370. Th.D.44 I.
Th.D460, 0.[.49/2. 1i.(1.26 16,
Tu.(.330. Tu.C.450, iu.C.453, Ti.D 2.45,
Tu.I.28 1/, [a D.2880.Tu.D.2930,
Tu.D.2959. (3(3D4/75,5A/e(.203.
We.(1.34 /0, We (.355/, We (.441,
We.(1.443, We.(1.583, We.D. 3673,
We.D.3690, We.D.3'7 I9, We.D.3775,
We.D.3804, We.D.3808, VWe.D.3809,
We.D.3810. We.[3.381 I,We.D.38 18,
We.D.480, We.[2.482
prevention, other
Pub.(1 I205, Pub.1. 1264. Pub.D. I1406,
TL.(1.43 /4, T6.(1 4401, 1 b.C.444 7
Th.(1 4584,T6.(1.4834.Th.1). 134,

prevention, SEE heterosexuals
Mo.(1I632, Mo.D, I883, Mu.D. 1921,
Pub.C1. 1174, Pub.1. 1208, Po b.1. 1232,
[6(1.433. [6(1.4380. [b.c 4422.
36(1C.4526, [6(1.4799,11 -iC 48 3,
Tu.(.450,3' a.D.2699, V\e.(.3528.
We.D 3/98, We.D.3804
prevention, SEE IDUs
MoD.l /98. MoD. 1939, Pub.C.115IS,
I 6(1.46/5, -[u.(.252 3, Tu.(.2528,
[u.( 2529, Tu.(1.2533, We.(1.3.5 IS,
We.(1.3536. We.(C.3546,V/e.(1.3553.
We (.3554. \Ne.(1.3556, We.(1.356 I,
\Ne.D.3799, We.D.480
prevention, SEE prisoners
MoD. I1845, MoD,362, Pu6.B I1042,
Pub.3. 1410. Pub.[3.141 1,16(1C.4430,
[.(.2549,-Iu.(.2623, TlU.(12628,
0.(.2663, Tu.(.2664, We.[2 35 I.
We.D.3 53, We.D.354, We. D. 3658,
We.D.38 14
prevention, SEE sex workers
Ma.(1.442, MoD. I1851, Mo.D.603,
T 6(1.32 1,1.(.4360, Th.(.45/ I.
1 6(1.4684. 16.0.460, Th.[..462,
I.D.5033, 6.[.5035,1 6.D.5039,
16 D.5050, Tu.(1.2624,Tu.(1.263 I,
Tu.(.2666, lu.(1.26 /3, Tu.D.2802,
We.(1 15 0, We.(1.3596, We.(1.3602,
We.D.3 /98
prevention, SEE women
Mu.D. 192 1, Pub.(1.1219, Pub.D. 1335,
[6(1.439 I,1.(.4509,Th.(1.451I0.
T6.(1 4564, [6.(1.4620, T6.(.4645,
1 h.D.244,Tu.(1.2 I IlceD 2709,Tu (.2734,
Tu.D.27/8. Tu.D.2/87,Tha.[.2805,
We.(1.35 I18, We.D.3775, We.[D.3899
primary immune response
Tu.B.228 I, We.A,285, We.A.385,
We.A.392.
primary monocytes
Mo.A. 1004, Mo.A. 1056, Mo.A. 143,
PuL.C1.I I117, Th.A.4065
primers, oligomer
36 A.4035, Tu.A.2087
principal neutralising domain (PND)
antibodies
Mo.A.5 I 1, Pub.A.10l ll,-1.8.4284.
Tu.A.207 I, WeA.3 14
prisoners
Mo.1. 1532, Mo.[.1539, Mo (.16/7,
[lo.(1.225, MoD. I1845, Ma [.362.
Pub.D. 14 10, PuL.D. 141I I, Pub..14 12,
Pub.D. I1453, T.B.4 122, 1.C.44 30,
T6.(1.4636, T[6.0.4637,[6 C.464g.
16(1C.4782,16(3..4880, [6.125 189,
lu.B.236 I,lu.(.2548,1u.(1.2549,
Tu.(.2625, O.(1 2628,Tu.(1 2632,
Tu..2649,Tu.(.2653, Tu 0.2054,
T.(1 26SS, (3(1.2662, -I.(.2663,
Tu.(.43 I, bi..I132, Tu.2 /62_.
W7e.(1.357 I, We.D.3SO, Wtie [.35 I,
Wa:DI.35v,.(.353, 7(143.354,
Wa.(3.355, We.(3.356, WelD 3654,
We.Dl.3655, We.(3.3657, We.(3.3658,
Wa,(3,3659, We.(3.3660, We.D.3662,
Wa,(3,3663, We.(3.3o64, We,023665,

We B.3206, We.B.335/, We.B 3384,
We (.3451,We.(.3452, We (.3674

prognosis, CD4 lymphocytes
Mo.B. I1124. laoB. I1242, Mo.B. I46
Mo.B. 13S2,. Cil1, 1 L4.401 I,
Th.A.4039. [6..-41/i. k1-..2346,
lu.B.3 14, T(1..)242. A)A3053,
We.B,325 II ASK 1..36, vle.B.3380,
WaB.3384, Wa.0.4 )1 '(13443,
We.(1.3455
prognosis, laboratory markers
Mo.A. 10/2. Mu.B. 1340. Mo.B. 1342,
Mo B. 1343. Mo.B. 134S, Mo.B. I1346,
Mo.B. I1352, Mo.[.32 I. Mo.(1.323.
Pub.A. 1006. Pub.B. 10S6, Th.A.400 I,
Tc.A.4045, T6.B 4236, [Ic 8.4297,
Th.B.4298,Tu A.2005, 1u.A.38 I,
Tua.B.2332,Tu.B.2333, Iu.8.2345,
Tu.B.2356, We.A.30 I18, We.A.3042,
WeA.3049, We.A.306 I,Vve.A.3 105.
We.B.3380, We.B.3385, We.B.4 10,
We.B.41 3, We.(1.3427, We.(1.3455
prognosis, other
Mo.B.1346, MoB. 135 7, (-0.0.185.
Th.B.4209,Thc.B.426 I, Tu.B. I9 I,Tu.B.2240,
Tu.B.234 7, Ta 8.235 I, We.B.3346
prognosis, SEE children
WeB. 3338
prognosis, SEE heterosexuals
We.C.3395, We~.36 I15
prognosis, SEE IDUs
WeB.3359. We.8.3360
prognosis, SEE women
We.D.3679
program
Ma.C. 1568, Mo.D, ll. D 1804.
Mo.D. I1836, MoD. I855, Pub.1. 1200,
Pub.C. 1226, Pub.C:. I228, PuL.D. 1480,
T6.(1.4383, [6(1.445 I,Th.(1.4473.
Th.(.4542, T6(.4654, Th.(1.466 I.
TI.(.47 I.,[6.(.4/85,T6 (1.1786.
Th.(.4 797, Th.D.3 74, We.(1.3567,
We.(1,582, We.D.362.0, We.D.369 3,
We.D.3695, We.[2.3764, We.D.3870,
We.D.3887, We.D 3889, We.D.590
program evaluation
MoB. I 163, Ma.C. 1638. Ma.D. 1758,
MoD. 1/60, MoD. 1770, Mo. D.1.I772,
Mo01. 1/80, MaoD. 1 782, Mo.D. 1784,
MoD, 1799, Pub.C...;I120, Pub.(11 I92,
Pab.1. 1259, Pu6.D. 1306,.Pib.D. I1309.
Pub.D. I1409, PulcO').1Ii I8, P116.0.1.I473,
TlcB.4 I16 I, [I.C.4626, 76(1.47 II,
Th.(1.4749, 1I.(.4765. T16.014772.
T6.(1.4784, Th.C 4787.C (.4806.
Th.(1.48 I15, Th.(.4823, T6.C.483 3.
Th.(.4857, Th.D4866,1 1 01499 I,
Th.D.5008, Th.D.5008, [6.0.5012,
Th.D.5028, Tu.C.2628, (3(1.2642,
Th.(1.33 I,Tu.Dl.245,...2 792,Ta.D 281 1,
Tu.D.28 I 8,Tu.D.293 1,VWe (.120,
We.C1I24, We.(1203, We.(1.3536,
We.(1.583, W.D..36 32, We.D.3/22,
We.D.3764. We.D. 3797, We.D.3807,
We.D.3838, We.L.3848, '0e.D.3882,
We.D.3892, We.D..3893, We.D.3894,
We.D.591
program, national
Mo.B. I1163, MoC. 1565,. MaC. 1654.

Th.B.4352, Th.D.4962, 36.1.4963,
Tu.A.2003, Tu.A.2004, [a.A.2063,

Ta A.2088, Ta.A.2 83. iu.A.384, 1a.A.393,
Tu.B. I92, Tu.B 21 23,iau.8.2237,Tu.B.2234,
Ta. 8.2 28 1, Ta. 8.2 329. Tau.8.2 341,
Tu.B.2385,Tu.C.2462, We.A 263,
We.A 3046, Wa.A.304l, WeB. 3250,
We.8.325 I, We.B.3254, We B.3337,
We.B,3339, We.B.4 14, We.C.3393,
We..3413, V/a (.3456,. 'a(.3463,
We.C.3465
progression, anergy
Mo.A 140, Mo 8. 1353,l1u 8.2240,
Tu.8.2353. We.B.3346. \Ae.(1,3455
progression, anti-HIV antibodies
Pub.A. 10 10. We.A 3(115. WeeA. 3019,
We 8.3324
progression, asymptomatic stages
Mo.A.392, Ma.A.395, Mo.B. 1380,
Mo.1 I558, Tu A 2067, 1.B. I 90,Tu 8.192,
Tu.(.553, We 8.3384. We.(1.3467,
We.C.3468
progression, CDC stages
Ma.B. 120/, Ma.C. 1529, Th.A.162.
TI.A.4002,16.A.40!9. 0 0.2331.
Tu.(1.2520, Tu.C.430, We A.3042,
We.A.306 1, We.B.3 17, We B8 3382.
We.B.3384, We..4 I1, We.0.1 41.
We.(1.3452, 07a.(.l455, S/Oaf.'4 /;
progression, cofactors
MoBI 14 1. MaB. 125c0, MoB!"'
Mo.C. 1582, Mo.(1.324, Mo..1875.
Mo.[l. 1880, TI (.224,l3u.B 194 [1u..2I3 3,
Tu. B.2 I18 8 [Tu.B.22 I16. [u. B.2 33 I,
Tu.B.2 -3.5 Bcx.8.2383. Yu.(.2S2O.
We.B. 321 /, eVe B 3259, W '.B 3268,
V e.B.33 I12,V/e -'.33 29, A a 8.3334,
We. 8.3336, We.B.3384, We.C.3392.
Wa.C.3400, Wa.C.34 10, /e.G.3428.
We.(1.3454, Wa.(1.3 456. VW.(.345 7,
WeG.3462, We.(1.3465, We.C.34/8
progression, heterosexuals
Mo.C1. 1429, Ma.C. 149 I, Th.8.42 /0,
1 -h.(1 4480, Ta (1.2450. Tu.C.2488.
We.B.333I, We.(1.3392, f/a (1 3305,
We.D.36 10
progression, laboratory
Mo.A. 10 14. Mo.A. I I I, Mo.A. I I 1/,
Mo.B. 1336, Mo.B. I1340. Ma 8. 1 311.
Mo.B. 1345, MoB I1350, M iB.!'380,
T1.A.40 13. h.A 4(1 3, TIL.4352,
We.A.3049 VWe.A.3 05, WeB.3 12 I
WeBS. 5WVe 8.3330. We.(1.3'156
progression, other
Mo.B. 12/0, Mo.B. 131 8, Mo.01.I1876
Pub.(.1 I54.Tc.8. I 85
progression, parameters
MoA 10 14, Mo.A. I III., Mo.A.390,
Mo.A.392, Ma 8.1338, Mo.B 1371,
Mo.B.1380, Ma.B.293, Ma.C 325.
Pub.A. 1026, Pub.B.1084, Po.. 1154,
I 1.A.4034, Tu.A 2005. Tu./' 2060,
TA.A.2066,lTu.B.40 1, (3(1. S5i,
We.A.30 19, We A 3075. We.8.3 120,
We.B 32S1, ve.B.3334,WV e.(1 346/,
We.(1.3470
progression, SEE children
WaG.3435
progression, SEE gay men

0
U
cc
Le
0
cc
0
U)
CIO
cc
0
cc
a)
Cc

495